$AGLE $ACRX AGLE will announce clinical data soon they told it has really good expectation.

Our data confirm the safety and tolerability of SSTS in the management of postoperative pain, resulting in a high level of patient satisfaction and acceptance of pain control.

coupled with recent POSITIVE Phase 4 data.

Could easily see great data off the back of 50% enrollment.

I'm still amazed by the EB05 Data.

☺️ Would have loved to buy back double right now You win some You lose some No worries..EBO5 IS COMING over 600 patients enrolled, 2 arms of 300 filled We never got any level 6 data.

Data looks better than price action suggests

FTD and great initial data,

EBO1 DATA ➕️ EBO5 EMERGENCY USE APPROVAL 300% GAIN IN FIRST DAY OF MULTI-DAY RALLY

Please hit that $4.80+ on EB01 good data 🤞🤞

$EDSA Yeah.great idea, shorting a Fast Track drug with it's other top candidate *EB01 presenting Full P2 Data any day and lines of communication to FDA WIDE OPEN to finally get protocol and commencement of P3 US.

easy EB01 FULL P2 DATA FDA P3 DESIGN APPROVAL

I’ll be hanging around for that data 😉

The catalyst was topline data of the 7 PG patients who received 2400mg biweekly of vilo over a period of 26 weeks, resulting in fantastic efficacy.

$IFRX I’m excited to see Staidson’s covid data.

$IFRX From all the data that I have read and many of the results that have been showcased from some of the trial participants using IFX-1, it is obvious that the drug is truly beneficial and has many avenues it will hopefully be targeted for use in.